AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8148435 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group) for chronic fatigue syndrome (CFS)
Number of subjects: 22
Study 2459174 — intervention group
Group type: EXPERIMENTAL
Intervention: Compound 48/80 at 2.4 mg/ml
Number of subjects: 0
Study 2459174 — intervention group
Group type: EXPERIMENTAL
Intervention: Compound 48/80 at 0.6 mg/ml
Number of subjects: 0
Study 2459174 — intervention group
Group type: EXPERIMENTAL
Intervention: Compound 48/80 at concentrations less than 0.6 mg/ml
Number of subjects: 0
Study 29382813 — intervention group
Group type: EXPERIMENTAL
Intervention: Succinylated gelatin (12 ml/kg)
Number of subjects: 70
Study 29382813 — intervention group
Group type: COMPARATOR
Intervention: Lactated Ringer's solution
Number of subjects: 70
Study 29382813 — intervention group
Group type: COMPARATOR
Intervention: Hypertonic sodium chloride hydroxyethyl starch 40 injection
Number of subjects: 70
Study 27544892 — intervention group
Group type: EXPERIMENTAL
Intervention: Indocyanine Green (ICG) intravenous injection before carotid endarterectomy
Number of subjects: 8
Study 27544892 — intervention group
Group type: COMPARATOR
Intervention: Saline injection (Control)
Number of subjects: 8
Study 27544892 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary NIRF-OCT imaging in swine
Number of subjects: 8
Study 25642916 — intervention group
Group type: EXPERIMENTAL
Intervention: Agomelatine
Number of subjects: 40
Study 25642916 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine
Number of subjects: 40
Study 25642916 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 40
Study 23000323 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized Decision Support System (CDSS)
Number of subjects: 60
Study 23000323 — intervention group
Group type: COMPARATOR
Intervention: Regional guideline in paper format (Control)
Number of subjects: 60
Study 19748249 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate restriction diet (20-25% energy from carbohydrate) for 12 weeks
Number of subjects: 39
Study 19748249 — intervention group
Group type: COMPARATOR
Intervention: Combination treatment: Carbohydrate restriction diet for 6 weeks followed by American Heart Association diet (50-55% CHO) for an additional 6 weeks
Number of subjects: 39
Study 18444711 — intervention group
Group type: EXPERIMENTAL
Intervention: ADHD/Rx
Number of subjects: 94
Study 18444711 — intervention group
Group type: EXPERIMENTAL
Intervention: ADHD/TN
Number of subjects: 94
Study 18444711 — intervention group
Group type: EXPERIMENTAL
Intervention: ADHD groups
Number of subjects: 94
Study 16551147 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressant medication
Number of subjects: 267
Study 16551147 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 267
Study 16551147 — intervention group
Group type: COMPARATOR
Intervention: Community referral
Number of subjects: 267
Study 14737930 — intervention group
Group type: EXPERIMENTAL
Intervention: Long poles
Number of subjects: 7
Study 14737930 — intervention group
Group type: COMPARATOR
Intervention: Normal poles
Number of subjects: 7
Study 14737930 — intervention group
Group type: COMPARATOR
Intervention: Short poles
Number of subjects: 7
Study 10639539 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril (10 mg once per day orally)
Number of subjects: 9297
Study 10639539 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9297
Study 10639539 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril
Number of subjects: 9297
Study 9181442 — intervention group
Group type: EXPERIMENTAL
Intervention: Bolus injection
Number of subjects: 27
Study 9181442 — intervention group
Group type: COMPARATOR
Intervention: Drip infusion
Number of subjects: 27
Study 7694148 — intervention group
Group type: EXPERIMENTAL
Intervention: esc-BACOP (escalated doses of doxorubicin)
Number of subjects: 238
Study 7694148 — intervention group
Group type: COMPARATOR
Intervention: s-BACOP (standard doses of doxorubicin)
Number of subjects: 238
Study 3898228 — intervention group
Group type: EXPERIMENTAL
Intervention: desglycinamide arginine vasopressin (DGAVP)
Number of subjects: 0
Study 31666783 — intervention group
Group type: EXPERIMENTAL
Intervention: Parasitological confirmed malaria
Number of subjects: 484
Study 31666783 — intervention group
Group type: EXPERIMENTAL
Intervention: Living in rural residence
Number of subjects: 484
Study 31666783 — intervention group
Group type: EXPERIMENTAL
Intervention: Having educated mother
Number of subjects: 484
Study 31666783 — intervention group
Group type: EXPERIMENTAL
Intervention: Age of child
Number of subjects: 484
Study 31666783 — intervention group
Group type: EXPERIMENTAL
Intervention: Sex of child
Number of subjects: 484
Study 31666783 — intervention group
Group type: EXPERIMENTAL
Intervention: Not sleeping under ITN
Number of subjects: 484
Study 31666783 — intervention group
Group type: EXPERIMENTAL
Intervention: ITN availability
Number of subjects: 484
Study 31666783 — intervention group
Group type: EXPERIMENTAL
Intervention: History of malaria infection among family members
Number of subjects: 484
Study 28853340 — intervention group
Group type: EXPERIMENTAL
Intervention: Feeling consistently Good
Number of subjects: 387
Study 28853340 — intervention group
Group type: COMPARATOR
Intervention: Moderate reactions
Number of subjects: 387
Study 28853340 — intervention group
Group type: COMPARATOR
Intervention: Pronounced reactions
Number of subjects: 387
Study 28853340 — intervention group
Group type: COMPARATOR
Intervention: Neutral reactions
Number of subjects: 387
Study 28853340 — intervention group
Group type: COMPARATOR
Intervention: Pronounced pattern among Black subjects
Number of subjects: 387
Study 27448264 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 419
Study 27448264 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Systemic Therapy (BST)
Number of subjects: 419
Study 24616894 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise and educational-behavioral programme (EG)
Number of subjects: 41
Study 24616894 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 41
Study 21953578 — intervention group
Group type: EXPERIMENTAL
Intervention: Face-to-face sexual counseling (FF)
Number of subjects: 115
Study 21953578 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based sexual counseling (WEB1)
Number of subjects: 115
Study 21953578 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based sexual counseling (WEB2)
Number of subjects: 115
Study 21953578 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control (WL)
Number of subjects: 115
Study 20179144 — intervention group
Group type: EXPERIMENTAL
Intervention: TMD with VOO
Number of subjects: 90
Study 20179144 — intervention group
Group type: EXPERIMENTAL
Intervention: TMD with WOO
Number of subjects: 90
Study 20179144 — intervention group
Group type: COMPARATOR
Intervention: Control with participants' habitual diet
Number of subjects: 90
Study 17270578 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold Pressor Test with feminine introductions
Number of subjects: 151
Study 17270578 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold Pressor Test with masculine introductions
Number of subjects: 151
Study 17270578 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold Pressor Test with gender-irrelevant introductions
Number of subjects: 151
Study 12780836 — intervention group
Group type: EXPERIMENTAL
Intervention: Transurethral electrovaporization of the prostate (TUVP)
Number of subjects: 180
Study 12780836 — intervention group
Group type: COMPARATOR
Intervention: Neodymium: YAG laser therapy
Number of subjects: 180
Study 10850578 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant activated factor VII (rFVIIa; NovoSeven) as a single intravenous bolus dose
Number of subjects: 36
Study 10850578 — intervention group
Group type: COMPARATOR
Intervention: Saline (control group)
Number of subjects: 36
Study 15321288 — intervention group
Group type: EXPERIMENTAL
Intervention: Meptazinol (10 mg PCA bolus)
Number of subjects: 48
Study 15321288 — intervention group
Group type: COMPARATOR
Intervention: Morphine (1 mg PCA bolus)
Number of subjects: 48
Study 8238798 — intervention group
Group type: EXPERIMENTAL
Intervention: loratadine 10 mg daily for 2 weeks
Number of subjects: 76
Study 8238798 — intervention group
Group type: EXPERIMENTAL
Intervention: terfenadine 60 mg twice daily for 2 weeks
Number of subjects: 76
Study 8238798 — intervention group
Group type: EXPERIMENTAL
Intervention: loratadine after crossover for nonresponders to terfenadine
Number of subjects: 76
Study 8238798 — intervention group
Group type: EXPERIMENTAL
Intervention: terfenadine after crossover for nonresponders to loratadine
Number of subjects: 76
Study 3884566 — intervention group
Group type: EXPERIMENTAL
Intervention: latamoxef (moxalactam)
Number of subjects: 60
Study 3884566 — intervention group
Group type: COMPARATOR
Intervention: cephradine plus tobramycin
Number of subjects: 60
Study 31010031 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific collagen peptides (SCP) 15 g daily
Number of subjects: 77
Study 31010031 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 77
Study 28834186 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone alone (n = 27)
Number of subjects: 75
Study 28834186 — intervention group
Group type: EXPERIMENTAL
Intervention: Osmotic dilators with mifepristone (n = 27)
Number of subjects: 75
Study 28834186 — intervention group
Group type: COMPARATOR
Intervention: Osmotic dilators with placebo (n = 21)
Number of subjects: 75
Study 28834186 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 75
Study 25230069 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol (4mg)
Number of subjects: 12
Study 25230069 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 23625328 — intervention group
Group type: EXPERIMENTAL
Intervention: Nintedanib 200 mg twice daily
Number of subjects: 64
Study 21799398 — intervention group
Group type: EXPERIMENTAL
Intervention: Fresh Frozen Plasma (FFP)
Number of subjects: 48
Study 21799398 — intervention group
Group type: EXPERIMENTAL
Intervention: Antithrombin III (ATIII)
Number of subjects: 48
Study 21799398 — intervention group
Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 48
Study 19548488 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorine dioxide waterline cleaner treatment
Number of subjects: 6
Study 19548488 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated lines)
Number of subjects: 6
Study 17806055 — intervention group
Group type: EXPERIMENTAL
Intervention: Micafungin 100 mg daily
Number of subjects: 595
Study 17806055 — intervention group
Group type: EXPERIMENTAL
Intervention: Micafungin 150 mg daily
Number of subjects: 595
Study 17806055 — intervention group
Group type: COMPARATOR
Intervention: Caspofungin (70 mg followed by 50 mg daily)
Number of subjects: 595
Study 17806055 — intervention group
Group type: COMPARATOR
Intervention: Caspofungin
Number of subjects: 595
Study 17806055 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 595
Study 15471825 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol, 50 mg/d
Number of subjects: 36
Study 15471825 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol, 100 mg/d
Number of subjects: 36
Study 15471825 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol or Metoprolol
Number of subjects: 36
Study 11058707 — intervention group
Group type: EXPERIMENTAL
Intervention: Omacor (4 g/day)
Number of subjects: 28
Study 11058707 — intervention group
Group type: COMPARATOR
Intervention: gemfibrozil (1200 mg/day)
Number of subjects: 28
Study 8874910 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisatracurium (0.1 mg. kg‐1)
Number of subjects: 80
Study 8874910 — intervention group
Group type: COMPARATOR
Intervention: Atracurium (0.5 mg. kg‐1)
Number of subjects: 80
Study 8874910 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisatracurium (0.15 mg. kg‐1)
Number of subjects: 80
Study 8874910 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisatracurium (0.2 mg. kg‐1)
Number of subjects: 80
Study 8874910 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisatracurium (2 x ED95 doses)
Number of subjects: 80
Study 8874910 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisatracurium (3 x ED95 doses)
Number of subjects: 80
Study 8874910 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisatracurium (4 x ED95 doses)
Number of subjects: 80
Study 1328143 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparins (LMW-heparins) administered subcutaneously
Number of subjects: 0
Study 1328143 — intervention group
Group type: COMPARATOR
Intervention: Classical intravenous heparin therapy
Number of subjects: 0
Study 4061268 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous timolol
Number of subjects: 20
Study 4061268 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 30509746 — intervention group
Group type: EXPERIMENTAL
Intervention: Trifocal spherical hydrophilic IOL (FineVision POD F)
Number of subjects: 0
Study 30509746 — intervention group
Group type: EXPERIMENTAL
Intervention: Trifocal toric hydrophilic IOL (FineVision POD FT)
Number of subjects: 0
Study 30509746 — intervention group
Group type: COMPARATOR
Intervention: Both IOLs
Number of subjects: 0
Study 29316152 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) injection
Number of subjects: 20
Study 29316152 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboxytherapy session
Number of subjects: 20
Study 29316152 — intervention group
Group type: COMPARATOR
Intervention: Carboxytherapy
Number of subjects: 20
Study 29316152 — intervention group
Group type: COMPARATOR
Intervention: Platelet-rich plasma (PRP)
Number of subjects: 20
Study 27760933 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy using FP(CF) plus docetaxel
Number of subjects: 0
Study 27760933 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy using FP(CF) plus radiation (FP(CF)-RT)
Number of subjects: 0
Study 27760933 — intervention group
Group type: COMPARATOR
Intervention: Neoadjuvant chemotherapy using FP(CF)
Number of subjects: 0
Study 27760933 — intervention group
Group type: COMPARATOR
Intervention: Neoadjuvant chemotherapy using DCF
Number of subjects: 0
Study 27760933 — intervention group
Group type: COMPARATOR
Intervention: Neoadjuvant chemotherapy using FP(CF)-RT
Number of subjects: 0
Study 25623102 — intervention group
Group type: EXPERIMENTAL
Intervention: PHILOS
Number of subjects: 284
Study 25623102 — intervention group
Group type: COMPARATOR
Intervention: LPHP
Number of subjects: 284
Study 24295145 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjoint Behavioral Consultation (CBC)
Number of subjects: 207
Study 24295145 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 207
Study 20585755 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical stimulation treatment (10 treatments vaginally and transanally over 5-7 weeks)
Number of subjects: 61
Study 20585755 — intervention group
Group type: COMPARATOR
Intervention: Tolterodine 4 mg orally once daily
Number of subjects: 61
Study 18180882 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk-powder-based dietary supplement providing 50 mg Ca, 250 mg Ca, or 500 mg Ca, or 500 mg Ca plus multivitamins, iron, and zinc, given daily, 6 days/week for 13 months.
Number of subjects: 158
Study 18180882 — intervention group
Group type: EXPERIMENTAL
Intervention: Milk-powder-based dietary supplement providing 50 mg Ca (lowest amount).
Number of subjects: 158
Study 18180882 — intervention group
Group type: COMPARATOR
Intervention: Pre-trial period (7 months) with no intervention.
Number of subjects: 158
Study 16868704 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard calcium and magnesium dialysis solution (SCa-MgD) (Ca: 1.62 mmol/l, Mg: 0.75 mmol/l)
Number of subjects: 46
Study 16868704 — intervention group
Group type: COMPARATOR
Intervention: Low calcium and magnesium dialysis solution (LCa-MgD) (Ca: 1.25 mmol/l, Mg: 0.25 mmol/l)
Number of subjects: 46
Study 16868704 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 46
Study 12786634 — intervention group
Group type: EXPERIMENTAL
Intervention: Pantoprazole, 20 mg daily for 6 months
Number of subjects: 164
Study 10958047 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermomagnetic bandages and belts worn for 8 hours a day for 14 consecutive days
Number of subjects: 60
Study 10958047 — intervention group
Group type: COMPARATOR
Intervention: Placebo (non-magnetic devices)
Number of subjects: 60
Study 8805033 — intervention group
Group type: COMPARATOR
Intervention: Growth hormone treatment in short normal children
Number of subjects: 50
Study 8805033 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy in children with acute lymphoblastic leukaemia
Number of subjects: 50
Study 8805033 — intervention group
Group type: COMPARATOR
Intervention: High-dose dexamethasone in babies with bronchopulmonary dysplasia
Number of subjects: 50
Study 1535301 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg intravenous methylprednisolone at 8 AM
Number of subjects: 6
Study 1535301 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg intravenous methylprednisolone at 4 PM
Number of subjects: 6
Study 1535301 — intervention group
Group type: COMPARATOR
Intervention: No drug administration
Number of subjects: 6
Study 31144279 — intervention group
Group type: EXPERIMENTAL
Intervention: Transitional Care (TC) intervention
Number of subjects: 654
Study 31144279 — intervention group
Group type: COMPARATOR
Intervention: Routine Care
Number of subjects: 654
Study 27614145 — intervention group
Group type: EXPERIMENTAL
Intervention: Midodrine
Number of subjects: 50
Study 27614145 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolvaptan
Number of subjects: 50
Study 27614145 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of midodrine and tolvaptan
Number of subjects: 50
Study 27614145 — intervention group
Group type: COMPARATOR
Intervention: Standard medical therapy (SMT)
Number of subjects: 50
Study 24963091 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation (NMES) applied during water swallows
Number of subjects: 26
Study 24963091 — intervention group
Group type: COMPARATOR
Intervention: Water swallows without NMES
Number of subjects: 26
Study 23370049 — intervention group
Group type: EXPERIMENTAL
Intervention: Yo-Yo intermittent recovery test level 1 (Yo-Yo IR1) training, 6-week program, twice a week
Number of subjects: 25
Study 23370049 — intervention group
Group type: COMPARATOR
Intervention: No training (control group)
Number of subjects: 25
Study 22171201 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure, Relaxation, and Rescripting Therapy (ERRT)
Number of subjects: 47
Study 22171201 — intervention group
Group type: COMPARATOR
Intervention: Waitlist Control
Number of subjects: 47
Study 21524761 — intervention group
Group type: EXPERIMENTAL
Intervention: QuantiFERON(®)-TB Gold In-Tube (QF)
Number of subjects: 376
Study 21524761 — intervention group
Group type: COMPARATOR
Intervention: Tuberculin skin test (PPD)
Number of subjects: 376
Study 17587516 — intervention group
Group type: EXPERIMENTAL
Intervention: isopropanolic extract of Actaea racemosa (iCR, Remifemin) 40 mg crude drug/day
Number of subjects: 244
Study 17587516 — intervention group
Group type: COMPARATOR
Intervention: tibolone 2.5 mg/day
Number of subjects: 244
Study 17587516 — intervention group
Group type: EXPERIMENTAL
Intervention: isopropanolic extract of Actaea racemosa (iCR, Remifemin)
Number of subjects: 244
Study 17587516 — intervention group
Group type: COMPARATOR
Intervention: tibolone
Number of subjects: 244
Study 16282305 — intervention group
Group type: EXPERIMENTAL
Intervention: Safe water system (SWS) with hygiene education
Number of subjects: 509
Study 16282305 — intervention group
Group type: EXPERIMENTAL
Intervention: Safe water system (SWS) with hygiene education and cotrimoxazole prophylaxis
Number of subjects: 509
Study 12015521 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral estrogen/medroxyprogesterone acetate (HRT)
Number of subjects: 43
Study 12015521 — intervention group
Group type: COMPARATOR
Intervention: Oral estrogen (ERT)
Number of subjects: 43
Study 12015521 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 9857542 — intervention group
Group type: EXPERIMENTAL
Intervention: Face-bow and Quick Master articulator
Number of subjects: 60
Study 9857542 — intervention group
Group type: COMPARATOR
Intervention: Traditional method (Gysi method)
Number of subjects: 60
Study 7818158 — intervention group
Group type: EXPERIMENTAL
Intervention: Capillary microscopy
Number of subjects: 522
Study 7818158 — intervention group
Group type: COMPARATOR
Intervention: Digital blood pressure measurements
Number of subjects: 522
Study 2211564 — intervention group
Group type: EXPERIMENTAL
Intervention: Buspirone
Number of subjects: 40
Study 2211564 — intervention group
Group type: COMPARATOR
Intervention: Lorazepam
Number of subjects: 40
Study 341947 — intervention group
Group type: EXPERIMENTAL
Intervention: Single night-time dose of mianserin 60 mg
Number of subjects: 50
Study 341947 — intervention group
Group type: COMPARATOR
Intervention: Three times daily regimen of mianserin
Number of subjects: 50
Study 341947 — intervention group
Group type: EXPERIMENTAL
Intervention: Mianserin plasma levels
Number of subjects: 50
Study 341947 — intervention group
Group type: EXPERIMENTAL
Intervention: Mianserin plasma levels above 70 microgram/1
Number of subjects: 50
Study 341947 — intervention group
Group type: EXPERIMENTAL
Intervention: Mianserin plasma levels in patients over 55
Number of subjects: 50
Study 31774552 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual nifedipine (20 mg loading dose, repeated every 30 minutes, maximum dose of 60 mg)
Number of subjects: 80
Study 31774552 — intervention group
Group type: COMPARATOR
Intervention: Oral nifedipine (20 mg loading dose, repeated every 30 minutes, maximum dose of 60 mg)
Number of subjects: 80
Study 31774552 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual nifedipine
Number of subjects: 80
Study 31774552 — intervention group
Group type: COMPARATOR
Intervention: Oral nifedipine
Number of subjects: 80
Study 31042649 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral interlaminar canal decompression
Number of subjects: 218
Study 31042649 — intervention group
Group type: COMPARATOR
Intervention: Classic laminectomy
Number of subjects: 218
Study 31042649 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 218
Study 28580357 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP)
Number of subjects: 14
Study 26237520 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose cholecalciferol (daily 50,000 IU vitamin D3)
Number of subjects: 230